Уровень N-концевого фрагмента предшественника мозгового натрийуретического пептида B-типа и атеросклеротическое поражение брахиоцефальных артерий у больных ревматоидным артритом с неэффективностью и/или непереносимостью базисной противовоспалительной тера
Уровень N-концевого фрагмента предшественника мозгового натрийуретического пептида B-типа и атеросклеротическое поражение брахиоцефальных артерий у больных ревматоидным артритом с неэффективностью и/или непереносимостью базисной противовоспалительной тера
Герасимова Е.В., Попкова Т.В., Мартынова А.В. и др. Уровень N-концевого фрагмента предшественника мозгового натрийуретического пептида B-типа и атеросклеротическое поражение брахиоцефальных артерий у больных ревматоидным артритом с неэффективностью и/или непереносимостью базисной противовоспалительной терапии. Терапевтический архив. 2019; 91 (5): 34–39. DOI: 10.26442/00403660.2019.05.000286
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Выявлена высокая прогностическая значимость концентрации N-концевого фрагмента предшественника мозгового натрийуретического пептида В-типа (N-terminal fragment of brain natriuretic peptide progenitor, NT-proBNP) в развитии сердечно-сосудистых заболеваний (ССЗ) при ревматоидном артрите (РА) и в общей популяции.
Цель: уточнить значение NT-proBNP у больных РА с неэффективностью и/или непереносимостью базисной противовоспалительной терапии, сопоставить уровень NT-proBNP с атеросклеротическим поражением брахиоцефальных артерий (БЦА), традиционными факторами риска (ТФР) ССЗ и маркерами воспаления.
Материалы и методы. Обследовано 28 пациентов с РА (24 женщины и 4 мужчин) с неэффективностью и/или непереносимостью базисных противовоспалительных препаратов (БПВП); медиана возраста составила 55 [46; 61] лет; продолжительность болезни – 114 [60; 168] мес; DAS28 – 6,2 [5,1; 7,0] балла; SDAI – 35,0 [23,9; 51,0], CDAI – 30,0 [21,0; 42,0]. Все больные были серопозитивны по ревматоидному фактору (РФ), 86% – по антителам к циклическому цитруллинированному пептиду (АЦЦП). Внесуставные проявления выявлялись у 54% больных. На момент включения в исследование 47% больных получали метотрексат (медиана дозы 20,2 [18; 25] мг/нед), 11% – лефлуномид, 7% – сульфасалазин, 46% – глюкокортикоиды, 75% – нестероидные противовоспалительные препараты. У 46% пациентов отмечена неэффективность 3 и более БПВП, у 54% – непереносимость предшествовавшей терапии БПВП. В исследование не включались пациенты с РА, имеющие хроническую сердечную недостаточность. У больных РА обнаружена высокая частота ТФР: артериальная гипертензия – у 75%, дислипидемия – 61%, курение – 17%, избыточная масса тела – 61%, отягощенная наследственность по ССЗ – 36%, гиподинамия – 68% больных. Ишемическую болезнь сердца диагностировали у 11% пациентов. Контрольную группу составили 20 здоровых доноров, сопоставимых с больными по возрасту и полу. Концентрацию NT-proBNP определяли в сыворотке крови методом электрохемилюминесценции (Roche Diagnostics, Швейцария). Всем пациентам проведено дуплексное сканирование экстракраниального отдела БЦА с определением толщины комплекса интима–медиа (КИМ). Атеросклеротическое поражение БЦА оценивали по наличию атеросклеротической бляшки (толщина КИМ≥1,2 мм).
Результаты. У пациентов с РА выявлены более высокие уровни NT-proBNP (78,7 [41,4; 101,3] пг/мл) по сравнению с группой здорового контроля (55,3 [36,6; 67,3] пг/мл, p<0,05). Пациентов с РА разделили на две группы по уровню NT-proBNP: >100 пг/мл – 1-я группа (n=6) и ≤100 пг/мл – 2-я группа (n=22). Группы больных РА не различались по полу, возрасту, активности РА, частоте выявления ТФР. Атеросклеротическое поражение БЦА выявлено у 3 (50%) пациентов 1-й группы и у 8 (36%) больных 2-й группы (р>0,05). У пациентов с РА уровень NT-proBNP положительно коррелировал с возрастом (r=0,39; p<0,05), с толщиной КИМ БЦА (r=0,43; p<0,05). У больных РА 2-й группы наблюдалась корреляционная связь между концентрацией NT-proBNP и уровнем антител к АЦЦП (r=0,42; p<0,05) и антител к модифицированному цитруллинированному виментину (анти-MCV; r=0,56; p<0,05). Связи концентрации NT-proBNP с активностью РА (DAS28, CDAI, CDAI), маркерами воспаления (С-реактивный белок, скорость оседания эритроцитов), ТФР и проводимой терапией установлено не было.
Заключение. Уровень NT-proBNP в крови больных РА с неэффективностью и/или непереносимостью базисной противовоспалительной терапии выше, чем в группе контроля. У каждого пятого больного РА концентрация NT-proBNP была выше 100 пг/мл. Продемонстрирована связь NT-proBNP с возрастом, иммунологическими показателями (АЦЦП и анти-МСV). Корреляция между концентрацией NT-proBNP и толщиной КИМ БЦА может свидетельствовать о возможной роли данного биомаркера в прогрессировании атеросклеротического поражения периферических артерий у больных РА. Значение NT-proBNP в развитии ранних проявлений атеросклероза при РА требует дальнейшего уточнения.
Ключевые слова: N-концевой фрагмент предшественника мозгового натрийуретического пептида В-типа, ревматоидный артрит, атеросклеротическое поражение брахиоцефальных артерий, традиционные факторы риска, сердечно-сосудистые заболевания.
Aim: to investigate the significance of NT-proBNP level in patients (pts) with RA with the ineffectiveness and/or intolerance of basic anti-inflammatory therapy; compare the level of NT-proBNP with atherosclerotic lesion of the brachiocephalic arteries (BCA), traditional risk factors and inflammatory markers.
Materials and methods. The investigation enrolled 28 pts (24women/4men) with the lack of efficacy/resistance and/or intolerance of basic anti-inflammatory drugs (DMARDs); median age was 55 [46; 61] years, median disease duration 114 [60; 168] month; DAS28 6,2 [5.1; 7.0]; SDAI 35.0[23.9; 51.0], CDAI 30.0[21.0; 42.0], serum positivity for rheumatoid factor (RF) (100%)/anti-cyclic citrullinated peptide antibodies (ACCP) (86%). The study did not include RA pts with congestive heart failure. High incidence of traditional risk factors was found in RA pts: arterial hypertension – in 75%, dyslipidemia – 61%, smoking – 17%, overweight – 61%, family history of cardiovascular diseases – 36%, hypodynamia – 68%. Coronary artery disease was diagnosed in 11% RA pts. Lack of efficacy of 3 or more DMARDs was found in 46% of pts, intolerance to previous therapy with DMARDs – in 54% pts. 47% were receiving methotrexate (20 [18; 25] mg/week), 11% – leflunomide, 7% – sulfasalazine, 46% – glucocorticoids, 75% – non-steroidal anti-inflammatory drugs. The control group consisted of 20 healthy donors, comparable to pts by age and sex. Serum levels of of NT-proBNP were measured using electrochemiluminescence method Elecsys proBNP II (Roche Diagnostics, Switzerland). The determination of the intima-media thickness (IMT) BCA were assessed from duplex scanning. Atherosclerotic lesion of BCA was assessed by the presence of atherosclerotic plaque (IMT ≥1.2 mm).
Results. NT-proBNP concentrations in RA pts proved to be higher (78.7 [41.4; 101.3] pg/ml) than those in the control group (55.3 [36.6; 67.3] pg/ml, p<0.05). RA pts were divided into two groups according to the level of NT-proBNP: >100 pg/ml – 1 group (n=6) and ≤100 pg/ml – 2 group (n=22). Groups of RA pts did not differ in gender, age, activity of RA, frequency of detection of traditional risk factors. Atherosclerotic lesion of the BCA was detected in 3 (50%) pts of the 1 group and in 8 (36%) pts of the 2 group (p>0.05). In RA pts the level of NT-proBNP correlated with age (r=0.39; p<0.05), with the IMT BCA (r=0.43; p<0.05). In RA pts of the 2 group, a correlation was observed between the concentration of NT-proBNP and the level of ACCP (r=0.42; p<0.05) and antibodies to modified citrullinated vimentin (anti-MCV; r=0.56; p<0.05). No association of NT-proBNP with PA activity (DAS28, CDAI, CDAI), inflammatory markers (C-reactive protein, erythrocyte sedimentation rate), traditional risk factors and therapy was found.
Conclusion. The level of NT-proBNP in the blood of RA pts with ineffectiveness and/or intolerance to basic anti-inflammatory therapy is higher than in the control group. In every fifth RA patient, the concentration of NT-proBNP was higher than 100 pg/ml. The association of NT-proBNP with age and immunological parameters (ACCP and anti-MCV) was demonstrated. The correlation between the concentration of NT-proBNP and the IMT BCA may indicate the possible role of this biomarker in the progression of atherosclerotic lesions of arteries in RA pts. The significance of NT-proBNP in the development of early manifestations of atherosclerosis in RA requires further study.
Keywords: N-terminal-pro-B-type natriuretic peptide, rheumatoid arthritis, atherosclerotic damage of brachocephalic arteries, traditional risk factors, cardiovascular diseases.
Цель: уточнить значение NT-proBNP у больных РА с неэффективностью и/или непереносимостью базисной противовоспалительной терапии, сопоставить уровень NT-proBNP с атеросклеротическим поражением брахиоцефальных артерий (БЦА), традиционными факторами риска (ТФР) ССЗ и маркерами воспаления.
Материалы и методы. Обследовано 28 пациентов с РА (24 женщины и 4 мужчин) с неэффективностью и/или непереносимостью базисных противовоспалительных препаратов (БПВП); медиана возраста составила 55 [46; 61] лет; продолжительность болезни – 114 [60; 168] мес; DAS28 – 6,2 [5,1; 7,0] балла; SDAI – 35,0 [23,9; 51,0], CDAI – 30,0 [21,0; 42,0]. Все больные были серопозитивны по ревматоидному фактору (РФ), 86% – по антителам к циклическому цитруллинированному пептиду (АЦЦП). Внесуставные проявления выявлялись у 54% больных. На момент включения в исследование 47% больных получали метотрексат (медиана дозы 20,2 [18; 25] мг/нед), 11% – лефлуномид, 7% – сульфасалазин, 46% – глюкокортикоиды, 75% – нестероидные противовоспалительные препараты. У 46% пациентов отмечена неэффективность 3 и более БПВП, у 54% – непереносимость предшествовавшей терапии БПВП. В исследование не включались пациенты с РА, имеющие хроническую сердечную недостаточность. У больных РА обнаружена высокая частота ТФР: артериальная гипертензия – у 75%, дислипидемия – 61%, курение – 17%, избыточная масса тела – 61%, отягощенная наследственность по ССЗ – 36%, гиподинамия – 68% больных. Ишемическую болезнь сердца диагностировали у 11% пациентов. Контрольную группу составили 20 здоровых доноров, сопоставимых с больными по возрасту и полу. Концентрацию NT-proBNP определяли в сыворотке крови методом электрохемилюминесценции (Roche Diagnostics, Швейцария). Всем пациентам проведено дуплексное сканирование экстракраниального отдела БЦА с определением толщины комплекса интима–медиа (КИМ). Атеросклеротическое поражение БЦА оценивали по наличию атеросклеротической бляшки (толщина КИМ≥1,2 мм).
Результаты. У пациентов с РА выявлены более высокие уровни NT-proBNP (78,7 [41,4; 101,3] пг/мл) по сравнению с группой здорового контроля (55,3 [36,6; 67,3] пг/мл, p<0,05). Пациентов с РА разделили на две группы по уровню NT-proBNP: >100 пг/мл – 1-я группа (n=6) и ≤100 пг/мл – 2-я группа (n=22). Группы больных РА не различались по полу, возрасту, активности РА, частоте выявления ТФР. Атеросклеротическое поражение БЦА выявлено у 3 (50%) пациентов 1-й группы и у 8 (36%) больных 2-й группы (р>0,05). У пациентов с РА уровень NT-proBNP положительно коррелировал с возрастом (r=0,39; p<0,05), с толщиной КИМ БЦА (r=0,43; p<0,05). У больных РА 2-й группы наблюдалась корреляционная связь между концентрацией NT-proBNP и уровнем антител к АЦЦП (r=0,42; p<0,05) и антител к модифицированному цитруллинированному виментину (анти-MCV; r=0,56; p<0,05). Связи концентрации NT-proBNP с активностью РА (DAS28, CDAI, CDAI), маркерами воспаления (С-реактивный белок, скорость оседания эритроцитов), ТФР и проводимой терапией установлено не было.
Заключение. Уровень NT-proBNP в крови больных РА с неэффективностью и/или непереносимостью базисной противовоспалительной терапии выше, чем в группе контроля. У каждого пятого больного РА концентрация NT-proBNP была выше 100 пг/мл. Продемонстрирована связь NT-proBNP с возрастом, иммунологическими показателями (АЦЦП и анти-МСV). Корреляция между концентрацией NT-proBNP и толщиной КИМ БЦА может свидетельствовать о возможной роли данного биомаркера в прогрессировании атеросклеротического поражения периферических артерий у больных РА. Значение NT-proBNP в развитии ранних проявлений атеросклероза при РА требует дальнейшего уточнения.
Ключевые слова: N-концевой фрагмент предшественника мозгового натрийуретического пептида В-типа, ревматоидный артрит, атеросклеротическое поражение брахиоцефальных артерий, традиционные факторы риска, сердечно-сосудистые заболевания.
________________________________________________
Aim: to investigate the significance of NT-proBNP level in patients (pts) with RA with the ineffectiveness and/or intolerance of basic anti-inflammatory therapy; compare the level of NT-proBNP with atherosclerotic lesion of the brachiocephalic arteries (BCA), traditional risk factors and inflammatory markers.
Materials and methods. The investigation enrolled 28 pts (24women/4men) with the lack of efficacy/resistance and/or intolerance of basic anti-inflammatory drugs (DMARDs); median age was 55 [46; 61] years, median disease duration 114 [60; 168] month; DAS28 6,2 [5.1; 7.0]; SDAI 35.0[23.9; 51.0], CDAI 30.0[21.0; 42.0], serum positivity for rheumatoid factor (RF) (100%)/anti-cyclic citrullinated peptide antibodies (ACCP) (86%). The study did not include RA pts with congestive heart failure. High incidence of traditional risk factors was found in RA pts: arterial hypertension – in 75%, dyslipidemia – 61%, smoking – 17%, overweight – 61%, family history of cardiovascular diseases – 36%, hypodynamia – 68%. Coronary artery disease was diagnosed in 11% RA pts. Lack of efficacy of 3 or more DMARDs was found in 46% of pts, intolerance to previous therapy with DMARDs – in 54% pts. 47% were receiving methotrexate (20 [18; 25] mg/week), 11% – leflunomide, 7% – sulfasalazine, 46% – glucocorticoids, 75% – non-steroidal anti-inflammatory drugs. The control group consisted of 20 healthy donors, comparable to pts by age and sex. Serum levels of of NT-proBNP were measured using electrochemiluminescence method Elecsys proBNP II (Roche Diagnostics, Switzerland). The determination of the intima-media thickness (IMT) BCA were assessed from duplex scanning. Atherosclerotic lesion of BCA was assessed by the presence of atherosclerotic plaque (IMT ≥1.2 mm).
Results. NT-proBNP concentrations in RA pts proved to be higher (78.7 [41.4; 101.3] pg/ml) than those in the control group (55.3 [36.6; 67.3] pg/ml, p<0.05). RA pts were divided into two groups according to the level of NT-proBNP: >100 pg/ml – 1 group (n=6) and ≤100 pg/ml – 2 group (n=22). Groups of RA pts did not differ in gender, age, activity of RA, frequency of detection of traditional risk factors. Atherosclerotic lesion of the BCA was detected in 3 (50%) pts of the 1 group and in 8 (36%) pts of the 2 group (p>0.05). In RA pts the level of NT-proBNP correlated with age (r=0.39; p<0.05), with the IMT BCA (r=0.43; p<0.05). In RA pts of the 2 group, a correlation was observed between the concentration of NT-proBNP and the level of ACCP (r=0.42; p<0.05) and antibodies to modified citrullinated vimentin (anti-MCV; r=0.56; p<0.05). No association of NT-proBNP with PA activity (DAS28, CDAI, CDAI), inflammatory markers (C-reactive protein, erythrocyte sedimentation rate), traditional risk factors and therapy was found.
Conclusion. The level of NT-proBNP in the blood of RA pts with ineffectiveness and/or intolerance to basic anti-inflammatory therapy is higher than in the control group. In every fifth RA patient, the concentration of NT-proBNP was higher than 100 pg/ml. The association of NT-proBNP with age and immunological parameters (ACCP and anti-MCV) was demonstrated. The correlation between the concentration of NT-proBNP and the IMT BCA may indicate the possible role of this biomarker in the progression of atherosclerotic lesions of arteries in RA pts. The significance of NT-proBNP in the development of early manifestations of atherosclerosis in RA requires further study.
Keywords: N-terminal-pro-B-type natriuretic peptide, rheumatoid arthritis, atherosclerotic damage of brachocephalic arteries, traditional risk factors, cardiovascular diseases.
Список литературы
1. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. Под ред. Е.Л. Насонова. M.: ГЭОТАР-Медиа, 2010: 678-702 [Popkova TV, Novikova DS, Nasonov EL. Atherosclerosis in rheumatic diseases. In: Rheumatology: clinical guidelines. Pod red. EL. Nasonov. Moscow: GEOTAR-Media, 2010:678-702 (In Russ.)].
2. Corrales A, Dessein PH, Tsang L, et al. Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. Arthritis Res Ther. 2015;17:55. doi: 10.1186/s13075 -015-0576-7
3. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Сердечно-сосудистые заболевания при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2016;54(2):122-8 [Popkova TV, Novikova DS, Nasonov EL. Сardiovascular diseases in rheumatoid arthritis: latest data. Rheumatology Science and Practice. 2016;54(2):122-8 (In Russ.)]. doi: 10.14412/1995-4484-2016-122-128
4. Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016;75:341-7. doi: 10.1136/annrheumdis-2013-204987
5. Pope JE, Nevskaya T, Barra L, Parraga G. Carotid artery atherosclerosis in patients with active rheumatoid arthritis: predictors of plaque occurrence and progression over 24 weeks. Open Rheumatol J. 2016;10:49-59. doi: 10.2174/1874312901610010049
6. Rudolf Berger, Deddo Moertl, Sieglinde Peter, et al. N-Terminal Pro-B-Type Natriuretic Peptide-Guided, Intensive Patient Management in Addition to Multidisciplinary Care in Chronic Heart Failure. J Am Coll Cardiol. 2010;55:645. doi: 10.1016/j.jacc.2009.08.078
7. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646-59. doi: 10.1161/circresaha.113.300268
8. Cameron VA, Rademaker MT, Ellmers LJ, et al. Atrial and brain natriuretic peptide expression after myocardial infarction in sheep: ANP is synthesized by fibroblast infiltration the infarct. Endocrinology. 2000;141:4690-7. doi: 10.1210/endo.141.12.7847
9. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B‐type natriuretic peptides and cardiovascular risk: systematic review and meta‐analysis of 40 prospective studies. Circulation. 2009;120:2177-87. doi: 10.1161/ circulationaha.109.884866
10. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AHB, Christenson RH, for the NACB Writing Group. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e356-e375. doi: 10.1161/ CIRCULATIONAHA.107.182882
11. Vergaro G, Januzzi JL Jr, Cohen Solal A, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018 Nov 15;271:324-30. doi: 10.1016/j.ijcard.2018.04.006
12. Provan S, Angel K, Semb AG, et al. NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis. 2010 Nov;69(11):1946-50. doi: 10.1136/ard.2009.127704
13. Breunig M, Kleinert S, Lehmann S, et al. Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol. 2018;47(2):102-9. doi: 10.1080/03009742.2017.1337924 Epub 2017 Aug 16
14. Redfield M, Rodeheffer R, Jacobsen S, Mahoney D, Bailey K, Burnett J. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976-82.
15. Alehagen U, Goetze JP, Dahlström U. Reference intervals and decision limits for Btype natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clin Chim Acta. 2007;382:8-14. doi.org/10.1016/j.cca. 2007.03.005
16. Passino C, Poletti R, Fontana M, et al. Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008;46:1515-23. doi: 10.1515/CCLM.2008.293
17. Khan AM, Сheng S, Maqnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011;96:3242-9. doi: 10.1210/jc.2011-1182
18. Vergaro G, Januzzi J, Cohen Solal A, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018 Nov 15;271:324-30. doi: 10.1016/j.ijcard. 2018.04.006
19. Schultz M, Faber J, Kistorp C, et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf). 2004;60:54-9
20. Avouac J, Meune C, Chenevier-Gobeaux C, et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J Rheumatol. 2014;41(2):248-55. doi: 10.3899/jrheum.130713
21. Södergren A, Karp K, Bengtsson C, Möller B, Rantapää-Dahlqvist S, Wållberg-Jonsson S. The extent of subclinical atherosclerosis is partially predicted by the inflammatory load: a prospective study over 5 years in patients with rheumatoid arthritis and matched controls. J Rheumatol. 2015;42:935-42. doi: 10.3899/jrheum.140694
22. Targońska-Stępniak B, Piotrowski M, et al. Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis. Cardiovasc Ultrasound. 2018;16(1):18. doi: 10.1186/s12947-018-0136-9
23. Кириллова И.Г., Новикова Д.С., Попкова Т.В. и др. Уровень N-концевого натрийуретического пептида и диастолическая дисфункция у больных ранним ревматоидным артритом до назначения базисных противовоспалительных препаратов. Терапевтический архив. 2016;88(5):19-26 [Kirillova IG, Novikova DS, Popkova TV, et al. N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs. Therapeutic Archive. 2016;88(5):19-26 (In Russ.)]. doi: 10.17116/terarkh201688519-26
24. De Filippi CR, Christenson RH, Gottdiener JS, et al. Dynamic cardiovascular risk assessment in elderly people. The role of repeated n-terminal pro-b-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55:441-50. doi: 10.1016/j.jacc.2009.07.069
25. Zhou W, Ni Z, Yu Z, et al. Brain natriuretic peptide is related to carotid plaques and predicts atherosclerosis in pre-dialysis patients with chronic kidney disease. Eur J Intern Med. 2012;23:539-44. doi: 10.1016/j.ejim. 2012.06.001
26. Odden MC, Shlipak MG, Whitson HE, et al. Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study. Atherosclerosis. 2014 Nov;237(1):336-42. doi: 10.1016/j.atherosclerosis. 2014.09.012
27. Gan L, Feng C, Liu C, et al. Association between serum N-terminal pro-B-type natriuretic peptide levels and characteristics of coronary atherosclerotic plaque detected by coronary computed tomography angiography. Exp Ther Med. 2016 Aug;12(2):667-75. doi: 10.3892/etm. 2016.3371
28. Клинические рекомендации Российского кардиологического общества 2018 г. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение [Clinical recommendations of the Russian Society of Cardiology 2018. Heart failure: chronic (CHF) and acute decompensated. Diagnosis, prevention and treatment (In Russ.)]. http://scardio.ru/content/Guidelines/ Chronic%20(CHF)%20and%20acute%20decompensated%20(ADHF).pdf
29. Targońska-Stępniak B, Majdan M. Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis. Clin Rheumatol. 2011;30:61-9. doi: 10.1007/s10067-010-1622-0
30. Tomáš L, Lazúrová I, Oetterová M, et al. Left ventricular morphology and function in patients with rheumatoid arthritis. Wien Klin Wochenschr. 2013 May;125(9-10):233-8. doi: 10.1007/s00508-013-0349-8
31. Schau T, Gottwald M, Arbach O, et al. Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type. J Rheumatol. 2015 Nov;42(11): 2029-37. doi: 10.3899/jrheum.141647
32. Yokoe I, Kobayashi H, Kobayashi Y, et al. Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol. 2018 Sep;47(5):364-70. doi: 10.1080/03009742.2017.1418424
33. Lianza AC, Aikawa NE, Moraes JC, et al. Long-term evaluation of cardiac function in juvenile idiopathic arthritis under anti-TNF therapy. Clin Exp Rheumatol. 2014 Sep-Oct;32(5):754-9.
34. Breunig M, Kleinert S, Lehmann S, et al. Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol. 2018 Mar;47(2):102-9. doi: 10.1080/03009742.2017.1337 924
35. Giles JT, Fert-Bober J, Park J, et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012 Feb 24;14(1):R39. doi: 10.1186/ar3752
36. Tsuchida K, Tanabe K. Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice. J Cardiol. 2008;52:212-23. doi: 10.1016/j.jjcc.2008.07.007
37. Brune K, Katus HA, Moecks J, et al. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events form anti-inflammatory drugs: a pilot study. Clin Chem. 2008;54:1149-57. doi: 10.1373/clinchem.2007.097428
38. Mirjafari H, Welsh P, Verstappen SM, еt al. N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Ann Rheum Dis. 2014;73(4):684-90. doi: 10.1136/annrheumdis-2012-202848
39. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-infl ammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 2004; 36:505-13. doi: 10.1016/j.yjmcc.2004.01.001
40. Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med. 2004;42:627-36.
41. Passino C, Poletti R, Fontana M, et al. Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008;46(11):1515-23. doi: 10.1515/CCLM.2008.293
42. Shaw SM, Fildes JE, Puchałka CM, et al. BNP directly immunoregulates the innate immune system of cardiac transplant recipients in vitro. Transpl Immunol. 2009 Jan;20(3):199-202. doi: 10.1016/j.trim.2008.08.010
43. Kobayashi H, Kobayashi Y, Yokoe I, et al. Magnetic Resonance Imaging-Detected Myocardial Inflammation and Fibrosis in Rheumatoid Arthritis: Associations With Disease Characteristics and N-Terminal Pro-Brain Natriuretic Peptide Levels. Arthritis Care Res (Hoboken). 2017 Sep;69(9):1304-11. doi: 10.1002/acr.23138
2. Corrales A, Dessein PH, Tsang L, et al. Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. Arthritis Res Ther. 2015;17:55. doi: 10.1186/s13075 -015-0576-7
3. Popkova TV, Novikova DS, Nasonov EL. Сardiovascular diseases in rheumatoid arthritis: latest data. Rheumatology Science and Practice. 2016;54(2):122-8 (In Russ.). doi: 10.14412/1995-4484-2016-122-128
4. Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016;75:341-7. doi: 10.1136/annrheumdis-2013-204987
5. Pope JE, Nevskaya T, Barra L, Parraga G. Carotid artery atherosclerosis in patients with active rheumatoid arthritis: predictors of plaque occurrence and progression over 24 weeks. Open Rheumatol J. 2016;10:49-59. doi: 10.2174/1874312901610010049
6. Rudolf Berger, Deddo Moertl, Sieglinde Peter, et al. N-Terminal Pro-B-Type Natriuretic Peptide-Guided, Intensive Patient Management in Addition to Multidisciplinary Care in Chronic Heart Failure. J Am Coll Cardiol. 2010;55:645. doi: 10.1016/j.jacc.2009.08.078
7. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646-59. doi: 10.1161/circresaha.113.300268
8. Cameron VA, Rademaker MT, Ellmers LJ, et al. Atrial and brain natriuretic peptide expression after myocardial infarction in sheep: ANP is synthesized by fibroblast infiltration the infarct. Endocrinology. 2000;141:4690-7. doi: 10.1210/endo.141.12.7847
9. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B‐type natriuretic peptides and cardiovascular risk: systematic review and meta‐analysis of 40 prospective studies. Circulation. 2009;120:2177-87. doi: 10.1161/ circulationaha.109.884866
10. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AHB, Christenson RH, for the NACB Writing Group. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e356-e375. doi: 10.1161/ CIRCULATIONAHA.107.182882
11. Vergaro G, Januzzi JL Jr, Cohen Solal A, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018 Nov 15;271:324-30. doi: 10.1016/j.ijcard.2018.04.006
12. Provan S, Angel K, Semb AG, et al. NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis. 2010 Nov;69(11):1946-50. doi: 10.1136/ard.2009.127704
13. Breunig M, Kleinert S, Lehmann S, et al. Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol. 2018;47(2):102-9. doi: 10.1080/03009742.2017.1337924 Epub 2017 Aug 16
14. Redfield M, Rodeheffer R, Jacobsen S, Mahoney D, Bailey K, Burnett J. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976-82.
15. Alehagen U, Goetze JP, Dahlström U. Reference intervals and decision limits for Btype natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clin Chim Acta. 2007;382:8-14. doi.org/10.1016/j.cca. 2007.03.005
16. Passino C, Poletti R, Fontana M, et al. Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008;46:1515-23. doi: 10.1515/CCLM.2008.293
17. Khan AM, Сheng S, Maqnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011;96:3242-9. doi: 10.1210/jc.2011-1182
18. Vergaro G, Januzzi J, Cohen Solal A, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018 Nov 15;271:324-30. doi: 10.1016/j.ijcard. 2018.04.006
19. Schultz M, Faber J, Kistorp C, et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf). 2004;60:54-9
20. Avouac J, Meune C, Chenevier-Gobeaux C, et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J Rheumatol. 2014;41(2):248-55. doi: 10.3899/jrheum.130713
21. Södergren A, Karp K, Bengtsson C, Möller B, Rantapää-Dahlqvist S, Wållberg-Jonsson S. The extent of subclinical atherosclerosis is partially predicted by the inflammatory load: a prospective study over 5 years in patients with rheumatoid arthritis and matched controls. J Rheumatol. 2015;42:935-42. doi: 10.3899/jrheum.140694
22. Targońska-Stępniak B, Piotrowski M, et al. Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis. Cardiovasc Ultrasound. 2018;16(1):18. doi: 10.1186/s12947-018-0136-9
23. Kirillova IG, Novikova DS, Popkova TV, et al. N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs. Therapeutic Archive. 2016;88(5):19-26 (In Russ.). doi: 10.17116/terarkh201688519-26
24. De Filippi CR, Christenson RH, Gottdiener JS, et al. Dynamic cardiovascular risk assessment in elderly people. The role of repeated n-terminal pro-b-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55:441-50. doi: 10.1016/j.jacc.2009.07.069
25. Zhou W, Ni Z, Yu Z, et al. Brain natriuretic peptide is related to carotid plaques and predicts atherosclerosis in pre-dialysis patients with chronic kidney disease. Eur J Intern Med. 2012;23:539-44. doi: 10.1016/j.ejim. 2012.06.001
26. Odden MC, Shlipak MG, Whitson HE, et al. Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study. Atherosclerosis. 2014 Nov;237(1):336-42. doi: 10.1016/j.atherosclerosis. 2014.09.012
27. Gan L, Feng C, Liu C, et al. Association between serum N-terminal pro-B-type natriuretic peptide levels and characteristics of coronary atherosclerotic plaque detected by coronary computed tomography angiography. Exp Ther Med. 2016 Aug;12(2):667-75. doi: 10.3892/etm. 2016.3371
28. Clinical recommendations of the Russian Society of Cardiology 2018. Heart failure: chronic (CHF) and acute decompensated. Diagnosis, prevention and treatment (In Russ.). http://scardio.ru/content/Guidelines/ Chronic%20(CHF)%20and%20acute%20decompensated%20(ADHF).pdf
29. Targońska-Stępniak B, Majdan M. Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis. Clin Rheumatol. 2011;30:61-9. doi: 10.1007/s10067-010-1622-0
30. Tomáš L, Lazúrová I, Oetterová M, et al. Left ventricular morphology and function in patients with rheumatoid arthritis. Wien Klin Wochenschr. 2013 May;125(9-10):233-8. doi: 10.1007/s00508-013-0349-8
31. Schau T, Gottwald M, Arbach O, et al. Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type. J Rheumatol. 2015 Nov;42(11): 2029-37. doi: 10.3899/jrheum.141647
32. Yokoe I, Kobayashi H, Kobayashi Y, et al. Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol. 2018 Sep;47(5):364-70. doi: 10.1080/03009742.2017.1418424
33. Lianza AC, Aikawa NE, Moraes JC, et al. Long-term evaluation of cardiac function in juvenile idiopathic arthritis under anti-TNF therapy. Clin Exp Rheumatol. 2014 Sep-Oct;32(5):754-9.
34. Breunig M, Kleinert S, Lehmann S, et al. Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol. 2018 Mar;47(2):102-9. doi: 10.1080/03009742.2017.1337 924
35. Giles JT, Fert-Bober J, Park J, et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012 Feb 24;14(1):R39. doi: 10.1186/ar3752
36. Tsuchida K, Tanabe K. Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice. J Cardiol. 2008;52:212-23. doi: 10.1016/j.jjcc.2008.07.007
37. Brune K, Katus HA, Moecks J, et al. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events form anti-inflammatory drugs: a pilot study. Clin Chem. 2008;54:1149-57. doi: 10.1373/clinchem.2007.097428
38. Mirjafari H, Welsh P, Verstappen SM, еt al. N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Ann Rheum Dis. 2014;73(4):684-90. doi: 10.1136/annrheumdis-2012-202848
39. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-infl ammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 2004; 36:505-13. doi: 10.1016/j.yjmcc.2004.01.001
40. Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med. 2004;42:627-36.
41. Passino C, Poletti R, Fontana M, et al. Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008;46(11):1515-23. doi: 10.1515/CCLM.2008.293
42. Shaw SM, Fildes JE, Puchałka CM, et al. BNP directly immunoregulates the innate immune system of cardiac transplant recipients in vitro. Transpl Immunol. 2009 Jan;20(3):199-202. doi: 10.1016/j.trim.2008.08.010
43. Kobayashi H, Kobayashi Y, Yokoe I, et al. Magnetic Resonance Imaging-Detected Myocardial Inflammation and Fibrosis in Rheumatoid Arthritis: Associations With Disease Characteristics and N-Terminal Pro-Brain Natriuretic Peptide Levels. Arthritis Care Res (Hoboken). 2017 Sep;69(9):1304-11. doi: 10.1002/acr.23138
2. Corrales A, Dessein PH, Tsang L, et al. Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. Arthritis Res Ther. 2015;17:55. doi: 10.1186/s13075 -015-0576-7
3. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Сердечно-сосудистые заболевания при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2016;54(2):122-8 [Popkova TV, Novikova DS, Nasonov EL. Сardiovascular diseases in rheumatoid arthritis: latest data. Rheumatology Science and Practice. 2016;54(2):122-8 (In Russ.)]. doi: 10.14412/1995-4484-2016-122-128
4. Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016;75:341-7. doi: 10.1136/annrheumdis-2013-204987
5. Pope JE, Nevskaya T, Barra L, Parraga G. Carotid artery atherosclerosis in patients with active rheumatoid arthritis: predictors of plaque occurrence and progression over 24 weeks. Open Rheumatol J. 2016;10:49-59. doi: 10.2174/1874312901610010049
6. Rudolf Berger, Deddo Moertl, Sieglinde Peter, et al. N-Terminal Pro-B-Type Natriuretic Peptide-Guided, Intensive Patient Management in Addition to Multidisciplinary Care in Chronic Heart Failure. J Am Coll Cardiol. 2010;55:645. doi: 10.1016/j.jacc.2009.08.078
7. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646-59. doi: 10.1161/circresaha.113.300268
8. Cameron VA, Rademaker MT, Ellmers LJ, et al. Atrial and brain natriuretic peptide expression after myocardial infarction in sheep: ANP is synthesized by fibroblast infiltration the infarct. Endocrinology. 2000;141:4690-7. doi: 10.1210/endo.141.12.7847
9. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B‐type natriuretic peptides and cardiovascular risk: systematic review and meta‐analysis of 40 prospective studies. Circulation. 2009;120:2177-87. doi: 10.1161/ circulationaha.109.884866
10. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AHB, Christenson RH, for the NACB Writing Group. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e356-e375. doi: 10.1161/ CIRCULATIONAHA.107.182882
11. Vergaro G, Januzzi JL Jr, Cohen Solal A, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018 Nov 15;271:324-30. doi: 10.1016/j.ijcard.2018.04.006
12. Provan S, Angel K, Semb AG, et al. NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis. 2010 Nov;69(11):1946-50. doi: 10.1136/ard.2009.127704
13. Breunig M, Kleinert S, Lehmann S, et al. Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol. 2018;47(2):102-9. doi: 10.1080/03009742.2017.1337924 Epub 2017 Aug 16
14. Redfield M, Rodeheffer R, Jacobsen S, Mahoney D, Bailey K, Burnett J. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976-82.
15. Alehagen U, Goetze JP, Dahlström U. Reference intervals and decision limits for Btype natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clin Chim Acta. 2007;382:8-14. doi.org/10.1016/j.cca. 2007.03.005
16. Passino C, Poletti R, Fontana M, et al. Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008;46:1515-23. doi: 10.1515/CCLM.2008.293
17. Khan AM, Сheng S, Maqnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011;96:3242-9. doi: 10.1210/jc.2011-1182
18. Vergaro G, Januzzi J, Cohen Solal A, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018 Nov 15;271:324-30. doi: 10.1016/j.ijcard. 2018.04.006
19. Schultz M, Faber J, Kistorp C, et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf). 2004;60:54-9
20. Avouac J, Meune C, Chenevier-Gobeaux C, et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J Rheumatol. 2014;41(2):248-55. doi: 10.3899/jrheum.130713
21. Södergren A, Karp K, Bengtsson C, Möller B, Rantapää-Dahlqvist S, Wållberg-Jonsson S. The extent of subclinical atherosclerosis is partially predicted by the inflammatory load: a prospective study over 5 years in patients with rheumatoid arthritis and matched controls. J Rheumatol. 2015;42:935-42. doi: 10.3899/jrheum.140694
22. Targońska-Stępniak B, Piotrowski M, et al. Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis. Cardiovasc Ultrasound. 2018;16(1):18. doi: 10.1186/s12947-018-0136-9
23. Кириллова И.Г., Новикова Д.С., Попкова Т.В. и др. Уровень N-концевого натрийуретического пептида и диастолическая дисфункция у больных ранним ревматоидным артритом до назначения базисных противовоспалительных препаратов. Терапевтический архив. 2016;88(5):19-26 [Kirillova IG, Novikova DS, Popkova TV, et al. N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs. Therapeutic Archive. 2016;88(5):19-26 (In Russ.)]. doi: 10.17116/terarkh201688519-26
24. De Filippi CR, Christenson RH, Gottdiener JS, et al. Dynamic cardiovascular risk assessment in elderly people. The role of repeated n-terminal pro-b-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55:441-50. doi: 10.1016/j.jacc.2009.07.069
25. Zhou W, Ni Z, Yu Z, et al. Brain natriuretic peptide is related to carotid plaques and predicts atherosclerosis in pre-dialysis patients with chronic kidney disease. Eur J Intern Med. 2012;23:539-44. doi: 10.1016/j.ejim. 2012.06.001
26. Odden MC, Shlipak MG, Whitson HE, et al. Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study. Atherosclerosis. 2014 Nov;237(1):336-42. doi: 10.1016/j.atherosclerosis. 2014.09.012
27. Gan L, Feng C, Liu C, et al. Association between serum N-terminal pro-B-type natriuretic peptide levels and characteristics of coronary atherosclerotic plaque detected by coronary computed tomography angiography. Exp Ther Med. 2016 Aug;12(2):667-75. doi: 10.3892/etm. 2016.3371
28. Клинические рекомендации Российского кардиологического общества 2018 г. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение [Clinical recommendations of the Russian Society of Cardiology 2018. Heart failure: chronic (CHF) and acute decompensated. Diagnosis, prevention and treatment (In Russ.)]. http://scardio.ru/content/Guidelines/ Chronic%20(CHF)%20and%20acute%20decompensated%20(ADHF).pdf
29. Targońska-Stępniak B, Majdan M. Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis. Clin Rheumatol. 2011;30:61-9. doi: 10.1007/s10067-010-1622-0
30. Tomáš L, Lazúrová I, Oetterová M, et al. Left ventricular morphology and function in patients with rheumatoid arthritis. Wien Klin Wochenschr. 2013 May;125(9-10):233-8. doi: 10.1007/s00508-013-0349-8
31. Schau T, Gottwald M, Arbach O, et al. Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type. J Rheumatol. 2015 Nov;42(11): 2029-37. doi: 10.3899/jrheum.141647
32. Yokoe I, Kobayashi H, Kobayashi Y, et al. Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol. 2018 Sep;47(5):364-70. doi: 10.1080/03009742.2017.1418424
33. Lianza AC, Aikawa NE, Moraes JC, et al. Long-term evaluation of cardiac function in juvenile idiopathic arthritis under anti-TNF therapy. Clin Exp Rheumatol. 2014 Sep-Oct;32(5):754-9.
34. Breunig M, Kleinert S, Lehmann S, et al. Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol. 2018 Mar;47(2):102-9. doi: 10.1080/03009742.2017.1337 924
35. Giles JT, Fert-Bober J, Park J, et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012 Feb 24;14(1):R39. doi: 10.1186/ar3752
36. Tsuchida K, Tanabe K. Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice. J Cardiol. 2008;52:212-23. doi: 10.1016/j.jjcc.2008.07.007
37. Brune K, Katus HA, Moecks J, et al. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events form anti-inflammatory drugs: a pilot study. Clin Chem. 2008;54:1149-57. doi: 10.1373/clinchem.2007.097428
38. Mirjafari H, Welsh P, Verstappen SM, еt al. N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Ann Rheum Dis. 2014;73(4):684-90. doi: 10.1136/annrheumdis-2012-202848
39. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-infl ammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 2004; 36:505-13. doi: 10.1016/j.yjmcc.2004.01.001
40. Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med. 2004;42:627-36.
41. Passino C, Poletti R, Fontana M, et al. Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008;46(11):1515-23. doi: 10.1515/CCLM.2008.293
42. Shaw SM, Fildes JE, Puchałka CM, et al. BNP directly immunoregulates the innate immune system of cardiac transplant recipients in vitro. Transpl Immunol. 2009 Jan;20(3):199-202. doi: 10.1016/j.trim.2008.08.010
43. Kobayashi H, Kobayashi Y, Yokoe I, et al. Magnetic Resonance Imaging-Detected Myocardial Inflammation and Fibrosis in Rheumatoid Arthritis: Associations With Disease Characteristics and N-Terminal Pro-Brain Natriuretic Peptide Levels. Arthritis Care Res (Hoboken). 2017 Sep;69(9):1304-11. doi: 10.1002/acr.23138
________________________________________________
2. Corrales A, Dessein PH, Tsang L, et al. Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. Arthritis Res Ther. 2015;17:55. doi: 10.1186/s13075 -015-0576-7
3. Popkova TV, Novikova DS, Nasonov EL. Сardiovascular diseases in rheumatoid arthritis: latest data. Rheumatology Science and Practice. 2016;54(2):122-8 (In Russ.). doi: 10.14412/1995-4484-2016-122-128
4. Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016;75:341-7. doi: 10.1136/annrheumdis-2013-204987
5. Pope JE, Nevskaya T, Barra L, Parraga G. Carotid artery atherosclerosis in patients with active rheumatoid arthritis: predictors of plaque occurrence and progression over 24 weeks. Open Rheumatol J. 2016;10:49-59. doi: 10.2174/1874312901610010049
6. Rudolf Berger, Deddo Moertl, Sieglinde Peter, et al. N-Terminal Pro-B-Type Natriuretic Peptide-Guided, Intensive Patient Management in Addition to Multidisciplinary Care in Chronic Heart Failure. J Am Coll Cardiol. 2010;55:645. doi: 10.1016/j.jacc.2009.08.078
7. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646-59. doi: 10.1161/circresaha.113.300268
8. Cameron VA, Rademaker MT, Ellmers LJ, et al. Atrial and brain natriuretic peptide expression after myocardial infarction in sheep: ANP is synthesized by fibroblast infiltration the infarct. Endocrinology. 2000;141:4690-7. doi: 10.1210/endo.141.12.7847
9. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B‐type natriuretic peptides and cardiovascular risk: systematic review and meta‐analysis of 40 prospective studies. Circulation. 2009;120:2177-87. doi: 10.1161/ circulationaha.109.884866
10. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AHB, Christenson RH, for the NACB Writing Group. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e356-e375. doi: 10.1161/ CIRCULATIONAHA.107.182882
11. Vergaro G, Januzzi JL Jr, Cohen Solal A, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018 Nov 15;271:324-30. doi: 10.1016/j.ijcard.2018.04.006
12. Provan S, Angel K, Semb AG, et al. NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis. 2010 Nov;69(11):1946-50. doi: 10.1136/ard.2009.127704
13. Breunig M, Kleinert S, Lehmann S, et al. Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol. 2018;47(2):102-9. doi: 10.1080/03009742.2017.1337924 Epub 2017 Aug 16
14. Redfield M, Rodeheffer R, Jacobsen S, Mahoney D, Bailey K, Burnett J. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976-82.
15. Alehagen U, Goetze JP, Dahlström U. Reference intervals and decision limits for Btype natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clin Chim Acta. 2007;382:8-14. doi.org/10.1016/j.cca. 2007.03.005
16. Passino C, Poletti R, Fontana M, et al. Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008;46:1515-23. doi: 10.1515/CCLM.2008.293
17. Khan AM, Сheng S, Maqnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011;96:3242-9. doi: 10.1210/jc.2011-1182
18. Vergaro G, Januzzi J, Cohen Solal A, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018 Nov 15;271:324-30. doi: 10.1016/j.ijcard. 2018.04.006
19. Schultz M, Faber J, Kistorp C, et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf). 2004;60:54-9
20. Avouac J, Meune C, Chenevier-Gobeaux C, et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J Rheumatol. 2014;41(2):248-55. doi: 10.3899/jrheum.130713
21. Södergren A, Karp K, Bengtsson C, Möller B, Rantapää-Dahlqvist S, Wållberg-Jonsson S. The extent of subclinical atherosclerosis is partially predicted by the inflammatory load: a prospective study over 5 years in patients with rheumatoid arthritis and matched controls. J Rheumatol. 2015;42:935-42. doi: 10.3899/jrheum.140694
22. Targońska-Stępniak B, Piotrowski M, et al. Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis. Cardiovasc Ultrasound. 2018;16(1):18. doi: 10.1186/s12947-018-0136-9
23. Kirillova IG, Novikova DS, Popkova TV, et al. N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs. Therapeutic Archive. 2016;88(5):19-26 (In Russ.). doi: 10.17116/terarkh201688519-26
24. De Filippi CR, Christenson RH, Gottdiener JS, et al. Dynamic cardiovascular risk assessment in elderly people. The role of repeated n-terminal pro-b-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55:441-50. doi: 10.1016/j.jacc.2009.07.069
25. Zhou W, Ni Z, Yu Z, et al. Brain natriuretic peptide is related to carotid plaques and predicts atherosclerosis in pre-dialysis patients with chronic kidney disease. Eur J Intern Med. 2012;23:539-44. doi: 10.1016/j.ejim. 2012.06.001
26. Odden MC, Shlipak MG, Whitson HE, et al. Risk factors for cardiovascular disease across the spectrum of older age: the Cardiovascular Health Study. Atherosclerosis. 2014 Nov;237(1):336-42. doi: 10.1016/j.atherosclerosis. 2014.09.012
27. Gan L, Feng C, Liu C, et al. Association between serum N-terminal pro-B-type natriuretic peptide levels and characteristics of coronary atherosclerotic plaque detected by coronary computed tomography angiography. Exp Ther Med. 2016 Aug;12(2):667-75. doi: 10.3892/etm. 2016.3371
28. Clinical recommendations of the Russian Society of Cardiology 2018. Heart failure: chronic (CHF) and acute decompensated. Diagnosis, prevention and treatment (In Russ.). http://scardio.ru/content/Guidelines/ Chronic%20(CHF)%20and%20acute%20decompensated%20(ADHF).pdf
29. Targońska-Stępniak B, Majdan M. Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis. Clin Rheumatol. 2011;30:61-9. doi: 10.1007/s10067-010-1622-0
30. Tomáš L, Lazúrová I, Oetterová M, et al. Left ventricular morphology and function in patients with rheumatoid arthritis. Wien Klin Wochenschr. 2013 May;125(9-10):233-8. doi: 10.1007/s00508-013-0349-8
31. Schau T, Gottwald M, Arbach O, et al. Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type. J Rheumatol. 2015 Nov;42(11): 2029-37. doi: 10.3899/jrheum.141647
32. Yokoe I, Kobayashi H, Kobayashi Y, et al. Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol. 2018 Sep;47(5):364-70. doi: 10.1080/03009742.2017.1418424
33. Lianza AC, Aikawa NE, Moraes JC, et al. Long-term evaluation of cardiac function in juvenile idiopathic arthritis under anti-TNF therapy. Clin Exp Rheumatol. 2014 Sep-Oct;32(5):754-9.
34. Breunig M, Kleinert S, Lehmann S, et al. Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. Scand J Rheumatol. 2018 Mar;47(2):102-9. doi: 10.1080/03009742.2017.1337 924
35. Giles JT, Fert-Bober J, Park J, et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012 Feb 24;14(1):R39. doi: 10.1186/ar3752
36. Tsuchida K, Tanabe K. Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice. J Cardiol. 2008;52:212-23. doi: 10.1016/j.jjcc.2008.07.007
37. Brune K, Katus HA, Moecks J, et al. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events form anti-inflammatory drugs: a pilot study. Clin Chem. 2008;54:1149-57. doi: 10.1373/clinchem.2007.097428
38. Mirjafari H, Welsh P, Verstappen SM, еt al. N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Ann Rheum Dis. 2014;73(4):684-90. doi: 10.1136/annrheumdis-2012-202848
39. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-infl ammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 2004; 36:505-13. doi: 10.1016/j.yjmcc.2004.01.001
40. Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med. 2004;42:627-36.
41. Passino C, Poletti R, Fontana M, et al. Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008;46(11):1515-23. doi: 10.1515/CCLM.2008.293
42. Shaw SM, Fildes JE, Puchałka CM, et al. BNP directly immunoregulates the innate immune system of cardiac transplant recipients in vitro. Transpl Immunol. 2009 Jan;20(3):199-202. doi: 10.1016/j.trim.2008.08.010
43. Kobayashi H, Kobayashi Y, Yokoe I, et al. Magnetic Resonance Imaging-Detected Myocardial Inflammation and Fibrosis in Rheumatoid Arthritis: Associations With Disease Characteristics and N-Terminal Pro-Brain Natriuretic Peptide Levels. Arthritis Care Res (Hoboken). 2017 Sep;69(9):1304-11. doi: 10.1002/acr.23138
Авторы
Е.В. Герасимова, Т.В. Попкова, А.В. Мартынова, Е.И. Маркелова, Д.С. Новикова, И.Г. Кириллова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия
V.A. Nasonova Scientific and Research Institute of Rheumatology, Moscow, Russia
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия
________________________________________________
V.A. Nasonova Scientific and Research Institute of Rheumatology, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.